Dariusz M. Kowalski

27.2k total citations · 7 hit papers
173 papers, 3.8k citations indexed

About

Dariusz M. Kowalski is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Dariusz M. Kowalski has authored 173 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 121 papers in Pulmonary and Respiratory Medicine, 104 papers in Oncology and 25 papers in Surgery. Recurrent topics in Dariusz M. Kowalski's work include Lung Cancer Treatments and Mutations (97 papers), Cancer Immunotherapy and Biomarkers (49 papers) and Lung Cancer Research Studies (44 papers). Dariusz M. Kowalski is often cited by papers focused on Lung Cancer Treatments and Mutations (97 papers), Cancer Immunotherapy and Biomarkers (49 papers) and Lung Cancer Research Studies (44 papers). Dariusz M. Kowalski collaborates with scholars based in Poland, United States and Spain. Dariusz M. Kowalski's co-authors include Maciej Krzakowski, Byoung Chul Cho, Yi‐Long Wu, Ki Hyeong Lee, Paweł Krawczyk, Wu‐Chou Su, Silvia Novello, Jerónimo Rafael Rodríguez‐Cid, M. Catherine Pietanza and Tony Mok and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Dariusz M. Kowalski

157 papers receiving 3.7k citations

Hit Papers

Tremelimumab as second-line or third-line treatment in re... 2017 2026 2020 2023 2017 2020 2023 2023 2021 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial
    2017 304 citations Michele Maio, Joachim G.J.V. Aerts et al. profile →
  2. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
    2020 295 citations Myung‐Ju Ahn, Byoung Chul Cho et al. profile →
  3. Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC
    2023 263 citations Terufumi Kato, Filippo de Marinis et al. profile →
  4. Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study
    2023 233 citations Silvia Novello, Dariusz M. Kowalski et al. Journal of Clinical Oncology profile →
  5. Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer
    2021 162 citations Salma K. Jabbour, Ki Hyeong Lee et al. profile →
  6. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study
    2022 151 citations Gilberto de Castro, Iveta Kudaba et al. Journal of Clinical Oncology profile →
  7. Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET -Amplified Non–Small Cell Lung Cancer: TATTON
    2022 95 citations Myung‐Ju Ahn, Byoung Chul Cho et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dariusz M. Kowalski Poland 29 2.5k 2.5k 744 525 315 173 3.8k
Davey B. Daniel United States 19 2.1k 0.8× 2.2k 0.9× 538 0.7× 688 1.3× 362 1.1× 82 3.3k
Venice Archer United Kingdom 9 3.6k 1.4× 3.6k 1.4× 919 1.2× 663 1.3× 276 0.9× 16 4.6k
Enric Carcereny Spain 26 1.6k 0.6× 1.9k 0.8× 856 1.2× 515 1.0× 338 1.1× 183 2.9k
Janusz Rolski Poland 15 2.8k 1.1× 2.8k 1.1× 763 1.0× 800 1.5× 214 0.7× 45 4.2k
Ariel López-Chávez United States 18 1.9k 0.7× 2.8k 1.1× 821 1.1× 465 0.9× 575 1.8× 41 3.7k
Saiama N. Waqar United States 29 1.9k 0.7× 1.7k 0.7× 654 0.9× 551 1.0× 155 0.5× 143 2.9k
Simon Ekman Sweden 25 2.5k 1.0× 2.2k 0.9× 1.4k 1.9× 1.0k 1.9× 381 1.2× 116 4.2k
Vienna Ludovini Italy 33 2.0k 0.8× 2.1k 0.9× 1.3k 1.8× 900 1.7× 205 0.7× 102 3.5k
Christina S. Baik United States 27 1.8k 0.7× 2.1k 0.8× 1.3k 1.7× 685 1.3× 339 1.1× 116 3.5k
V.A. Miller United States 22 1.6k 0.6× 2.1k 0.8× 924 1.2× 508 1.0× 218 0.7× 83 3.0k

Countries citing papers authored by Dariusz M. Kowalski

Since Specialization
Citations

This map shows the geographic impact of Dariusz M. Kowalski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dariusz M. Kowalski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dariusz M. Kowalski more than expected).

Fields of papers citing papers by Dariusz M. Kowalski

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dariusz M. Kowalski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dariusz M. Kowalski. The network helps show where Dariusz M. Kowalski may publish in the future.

Co-authorship network of co-authors of Dariusz M. Kowalski

This figure shows the co-authorship network connecting the top 25 collaborators of Dariusz M. Kowalski. A scholar is included among the top collaborators of Dariusz M. Kowalski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dariusz M. Kowalski. Dariusz M. Kowalski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
4.
5.
6.
Rodríguez‐Abreu, Delvys, Byoung Chul Cho, Tibor Csőszi, et al.. (2024). Abstract CT253: Results from KEYNOTE-B99: Phase 2 study of first-line (1L) pembrolizumab (pembro) plus investigational agents and chemotherapy (chemo) for extensive-stage small-cell lung cancer (ES-SCLC). Cancer Research. 84(7_Supplement). CT253–CT253. 2 indexed citations
7.
Płużański, Adam, et al.. (2024). Pulmonary Benign Metastasizing Leiomyoma in a Postmenopausal Woman: A Case Report and Review of the Literature. SHILAP Revista de lepidopterología. 12(8). 181–181. 1 indexed citations
8.
Novello, Silvia, Dariusz M. Kowalski, Alexander Luft, et al.. (2023). Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study. Journal of Clinical Oncology. 41(11). 1999–2006. 233 indexed citations breakdown →
9.
Castro, Gilberto de, Iveta Kudaba, Yi‐Long Wu, et al.. (2022). Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study. Journal of Clinical Oncology. 41(11). 1986–1991. 151 indexed citations breakdown →
10.
Wojas‐Krawczyk, Kamila, et al.. (2022). Non-Small-Cell Lung Cancer Patients with Coexistence of High PD-L1 Expression and RET Fusion—Which Path Should We Follow? Case Reports and Literature Review. Journal of Clinical Medicine. 11(6). 1630–1630. 5 indexed citations
11.
Passaro, Antonio, Filippo de Marinis, Hai‐Yan Tu, et al.. (2021). Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies. Frontiers in Oncology. 11. 709877–709877. 12 indexed citations
12.
Kowalski, Dariusz M., et al.. (2021). Thymic epithelial tumors: Do we know all the prognostic factors?. Thoracic Cancer. 12(3). 339–348. 12 indexed citations
13.
Mazières, Julien, Dariusz M. Kowalski, Alexander Luft, et al.. (2019). Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 38(3). 271–280. 57 indexed citations
14.
Rzyman, Witold, Joanna Didkowska, Robert Dziedzic, et al.. (2018). Consensus Statement on a Screening Programme for the Detection of Early Lung Cancer in Poland. Advances in respiratory medicine. 86(1). 53–74. 14 indexed citations
15.
Kowalski, Dariusz M., et al.. (2018). Management of nivolumab-induced pulmonary toxicity — pneumonitis. Oncology in Clinical Practice. 14(1). 35–39. 1 indexed citations
16.
Jassem, Jacek, Wojciech Biernat, Maciej Bryl, et al.. (2014). The role of systemic therapies of non-small cell lung cancer and malignant pleural mesothelioma: updated expert recommendations. Oncology in Clinical Practice. 10(1). 1–15. 1 indexed citations
17.
Kowalski, Dariusz M., et al.. (2011). Epidermal growth factor receptor (EGFR) inhibition on non-small-cell lung cancer treatment. Oncology in Clinical Practice. 7(4). 177–182. 1 indexed citations
18.
Krawczyk, Paweł, Dariusz M. Kowalski, Kamila Wojas‐Krawczyk, Maciej Krzakowski, & Janusz Milanowski. (2011). TORAKOCHIRURGIA Do NSCLC patients become sensitive to second-line erlotinib treatment after previous radiotherapy?. 7(4). 411–414. 1 indexed citations
19.
Jassem, Jacek, Wojciech Biernat, Rafał Dziadziuszko, et al.. (2010). Uaktualnione zalecenia dotyczące systemowego leczenia niedrobnokomórkowego raka płuca i złośliwego międzybłoniaka opłucnej. Nowotwory Journal of Oncology. 4(3). 139–153. 1 indexed citations
20.
Kowalski, Dariusz M. & Maciej Krzakowski. (2003). New agents in chemotherapy of disseminated non-small cell lung cancer – real benefits. Contemporary Oncology/Współczesna Onkologia. 5(6). 278–284. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Davey B. Daniel Breakdown of academic impact, for papers by Venice Archer Breakdown of academic impact, for papers by Enric Carcereny Breakdown of academic impact, for papers by Janusz Rolski Breakdown of academic impact, for papers by Ariel López-Chávez Breakdown of academic impact, for papers by Saiama N. Waqar Breakdown of academic impact, for papers by Simon Ekman Breakdown of academic impact, for papers by Vienna Ludovini Breakdown of academic impact, for papers by Christina S. Baik Breakdown of academic impact, for papers by V.A. Miller
Rankless by CCL
2026